sub:assertion {
d:DB00872 dv:ddi-interactor-in dr:DB00872_DB06335 .
d:DB06335 dv:ddi-interactor-in dr:DB00872_DB06335 .
dr:DB00872_DB06335 dcterms:identifier "drugbank_resource:DB00872_DB06335" ;
dcterms:title "DDI between Conivaptan and Saxagliptin - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin. Limit saxagliptin dose to 2.5 mg/day and monitor for increased saxagliptin levels/effects (e.g., hypoglycemia) with concomitant administration of a strong CYP3A4 inhibitor (e.g., ketoconazole). Monitor for decreased saxagliptin levels/effects with discontinuation of concomitant CYP3A4 inhibitor."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Conivaptan and Saxagliptin - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin. Limit saxagliptin dose to 2.5 mg/day and monitor for increased saxagliptin levels/effects (e.g., hypoglycemia) with concomitant administration of a strong CYP3A4 inhibitor (e.g., ketoconazole). Monitor for decreased saxagliptin levels/effects with discontinuation of concomitant CYP3A4 inhibitor. [drugbank_resource:DB00872_DB06335]"@en .
}